- Opinion
- [Reproter's View] Have you forgotten what the MFDS does?
- by Lee, Tak-Sun Jan 8, 2021 06:21am
- It was expected that the politics and media would put pressure on the introduction of COVID-19 vaccine, but it is too blatant. They only emphasize rapid introduction forgetting the role of the MFDS in verifying the safety and effectiveness of vaccines. From the time President Trump pressed the US FDA, the independence of the MFDS was ex
- Company
- 51 Jardiance patent-challenging generics released in 4 years
- by Kim, Jin-Gu Jan 8, 2021 06:20am
- Six more pharmaceutical companies are to evade the patents on Boehringer Ingelheim Korea’s antidiabetic sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin). As a result, total 51 companies would be able to avoid charges on infringing the product’s patent. The pharmaceutical industry source reported on Jan. 7 tha
- Company
- Korean-made novel drug Kanarb keeps on evolving
- by Kim, Jin-Gu Jan 8, 2021 06:20am
- Boryung Pharmaceutical’s star Kanarb (fimasartan) has added a new indication after a decade. Now the drug is indicated to reduce proteinuria in a hypertensive diabetic patient. In the highly saturated market for angiotensin II receptor blocker (ARB) for hypertension, Kanarb has found a new weapon to break through the stagnated growth.
- Company
- SK Bioscience and GSK signed a joint sale of 5 vaccines
- by Kim, Jin-Gu Jan 8, 2021 06:19am
- SK Bioscience has signed a joint sales contract with GSK for five vaccines. SK Bioscience announced on the 6th that it has signed a co-promotion contract for major vaccines with GSK to expand the domestic vaccine market. This is the content that SK Biosciences jointly sells and distributes vaccines developed by GSK in Korea. These prod
- Policy
- Boehringer's new obesity drug is conducting clinical trial
- by Lee, Tak-Sun Jan 8, 2021 06:19am
- Boehringer Ingelheim is conducting a clinical trial of a new obesity treatment in Korea. It is noteworthy whether it will exceed the sales of Saxenda (Liraglutide·NovoNordisk), which is currently leading in the Korean market. The MFDS approved the Phase II clinical trial protocol of BI 456906, a candidate for the new obesity drug of Boehr
- Policy
- We'll respond more aggressively through vaccines & tx
- by Kim, Jung-Ju Jan 8, 2021 06:19am
- President Moon Jae-in predicted that it will be able to respond more aggressively to COVID-19 as the commercialization and supply of vaccines and treatments will become reality next month. In particular, President Moon predicted that it would become a model country equipped with quarantine, vaccines, and treatments if commercialized, such
- Product
- What are the latest COVID-19 drug guidelines?
- by Choi, sun Jan 8, 2021 06:19am
- As COVID-19 pandemic has passed a year, the guidelines for drug use are being updated a lot. As the evidence was accumulated, the differences in the guidelines for use by each country decreased, and detailed recommendations for practical use were derived with recommendations for use and refraining from various cases even with the same drug.
- Company
- Cyramza·Tarceva therapy is expected to be proposed
- by Eo, Yun-Ho Jan 8, 2021 06:19am
- It is noteworthy whether the first combination option of targeted anticancer drugs to enter insurance coverage in the first-line lung cancer therapy will be possible. According to related industries, first-line therapy for non-small cell lung cancer (NSCLC) VEGF receptor 2 antagonist Cyramza (Ramucirumab) and epithelial cell growth factor
- Company
- Mitsubishi Tanabe licensed to market narcolepsy drug Wakix
- by Jan 8, 2021 06:18am
- On Jan. 4, Mitsubishi Tanabe Pharma Korea (CEO : Yomogida Osamu) announced the Ministry of Food and Drug Safety (MFDS) has green lit a narcolepsy treatment Wakix Film Coated Tablet (pitolisant hydrochloride) on Dec. 30, 2020, for marketing in the South Korean market. Wakix is indicated to treat cataplexy in adult patients with narcolepsy
- Company
- SK Chemical's Ongentys can be prescribed at BIG 5
- by Eo, Yun-Ho Jan 6, 2021 06:20am
- SK Chemicals' Ongentys can be prescribed in general hospitals. According to related industries, the 3rd generation COMT inhibitor Ongentys (Opicapone) has passed the drug commitee (DC) of Big 5 hospitals such as SNUH, AMC, and Shinchon Severance Hospital. Ongentys, which was listed at a drug price of &8361;2,515 last October after domesti
